Yu Peng Li
Directeur/Membre du Conseil chez MabPlex International Co., Ltd.
Postes actifs de Yu Peng Li
Sociétés | Poste | Début | Fin |
---|---|---|---|
MabPlex International Co., Ltd.
MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China. | Directeur/Membre du Conseil | 01/12/2019 | - |
Historique de carrière de Yu Peng Li
Anciens postes connus de Yu Peng Li
Sociétés | Poste | Début | Fin |
---|---|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | 01/11/2020 | 01/12/2023 |
Formation de Yu Peng Li
Chinese Academy of Fiscal Sciences | Graduate Degree |
Statistiques
Internationale
Chine | 4 |
Opérationnelle
Director/Board Member | 2 |
Graduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Health Technology |
MabPlex International Co., Ltd.
MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China. | Health Technology |
- Bourse
- Insiders
- Yu Peng Li
- Expérience